These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 34371128)

  • 1. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
    Tang F; Tie Y; Wei YQ; Tu CQ; Wei XW
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188606. PubMed ID: 34371128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
    Zhu MMT; Shenasa E; Nielsen TO
    Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
    Italiano A; Bellera C; D'Angelo S
    J Hematol Oncol; 2020 May; 13(1):55. PubMed ID: 32430039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
    Banks LB; D'Angelo SP
    J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies and checkpoint inhibitors in sarcoma.
    Vasella M; Gousopoulos E; Guidi M; Storti G; Song SY; Grieb G; Pauli C; Lindenblatt N; Giovanoli P; Kim BS
    QJM; 2022 Dec; 115(12):793-805. PubMed ID: 33486519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Sarcoma: Current Data and Promising Strategies.
    Wood GE; Meyer C; Petitprez F; D'Angelo SP
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432234. PubMed ID: 38781557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
    Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
    Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy and Biomarkers in Sarcoma.
    Dajsakdipon T; Siripoon T; Ngamphaiboon N; Ativitavas T; Dejthevaporn T
    Curr Treat Options Oncol; 2022 Mar; 23(3):415-438. PubMed ID: 35262852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in Sarcoma: Where Do Things Stand?
    Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
    Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in soft-tissue sarcoma.
    Ayodele O; Razak ARA
    Curr Oncol; 2020 Feb; 27(Suppl 1):17-23. PubMed ID: 32174754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.
    Hildebrand KM; Singla AK; McNeil R; Marritt KL; Hildebrand KN; Zemp F; Rajwani J; Itani D; Bose P; Mahoney DJ; Jirik FR; Monument MJ
    PLoS One; 2021; 16(7):e0253864. PubMed ID: 34242269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.
    Jeong S; Afroz S; Kang D; Noh J; Suh J; Kim JH; You HJ; Kang HG; Kim YJ; Kim JH
    Mol Cells; 2023 Oct; 46(10):579-588. PubMed ID: 37853684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next frontiers in systemic therapy for soft tissue sarcoma.
    Yen CC; Chen TW
    Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy Combined with Intralesional Immunostimulatory Agents for Soft Tissue Sarcomas.
    Su C; Kim SK; Wang CX; Kirsch DG; Monjazeb AM
    Semin Radiat Oncol; 2024 Apr; 34(2):243-257. PubMed ID: 38508788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of immunotherapy for the treatment of sarcoma.
    Klemen ND; Kelly CM; Bartlett EK
    J Surg Oncol; 2021 Mar; 123(3):730-738. PubMed ID: 33259653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic approaches to sarcoma.
    Burgess M; Tawbi H
    Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Targeted and Immune-Based Therapies in Sarcoma.
    Pollack SM; Ingham M; Spraker MB; Schwartz GK
    J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.
    Groisberg R; Hong DS; Behrang A; Hess K; Janku F; Piha-Paul S; Naing A; Fu S; Benjamin R; Patel S; Somaiah N; Conley A; Meric-Bernstam F; Subbiah V
    J Immunother Cancer; 2017 Dec; 5(1):100. PubMed ID: 29254498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.